EyePoint (EYPT) Jefferies Global Healthcare Conference 2026 summary

Clinical development updates

• Lead product DURAVYU (EYP-1901) is in four phase III trials: two for wet AMD (LUGANO, LUCIA) and two for DME (COMO, CAPRI), with wet AMD trials fully enrolled and DME trials nearly two-thirds enrolled.

• LUGANO trial readout expected in August, LUCIA about two months later; last patient visit for wet AMD in about a month.

• DME trials are enrolling rapidly, with last patient expected in Q3 2024 and top-line data anticipated about a year later.

• Primary endpoint for wet AMD is non-inferiority in visual acuity at week 52/56 versus Eylea; phase II data showed strong non-inferiority.

• Safety profile remains strong, with no significant safety signals or protocol changes recommended by the data monitoring committee.

Key efficacy and safety considerations

• Statistical non-inferiority in visual acuity is the main efficacy goal; small differences in letters are not clinically meaningful to practitioners.

• Safety is closely monitored, with no ocular systemic SAEs reported in prior trials and ongoing masked safety reviews in phase III.

• Reduction in treatment burden is a major value proposition; a 20% or greater reduction is considered clinically meaningful, with only 8% needed for statistical superiority.

• In phase II, about 50% of eyes were rescue-free at one year with a single injection; real-world use may involve combination with biologics.

• Sustained VEGF suppression is believed to improve long-term visual outcomes.

Real-world application and market dynamics

• Real-world treatment is expected to use a treat-and-extend approach, alternating DURAVYU and biologics, potentially reducing injections by a third.

• Doctors may prefer over-treating to avoid under-treatment, with individualized therapy based on patient response.

• Market for retinal vascular diseases in the U.S. is projected at $13 billion in 2025, with high single-digit growth rates.

• Sustained release therapies are seen as the top unmet need by retina specialists.

• Strategic partners view the space as a large opportunity, with DME alone representing a $3 billion U.S. market.